tiprankstipranks
Kymera Therapeutics, Inc. (KYMR)
NASDAQ:KYMR
US Market
KYMR
Kymera Therapeutics
RESEARCH TOOLSreports
Want to see KYMR full AI Analyst Report?

Kymera Therapeutics (KYMR) Stock Forecast & Price Target

445 Followers
See the Price Targets and Ratings of:

KYMR Analyst Ratings

Strong Buy
18Ratings
Strong Buy
16 Buy
2 Hold
0 Sell
Based on 18 analysts giving stock ratings to
Kymera
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

KYMR Stock 12 Month Forecast

Average Price Target

$131.33
▲(18.78% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for Kymera Therapeutics in the last 3 months. The average price target is $131.33 with a high forecast of $155.00 and a low forecast of $112.00. The average price target represents a 18.78% change from the last price of $110.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"39":"$39","156":"$156","68.25":"$68.3","97.5":"$97.5","126.75":"$126.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":155,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$155.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":131.33333333333334,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$131.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$112.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[39,68.25,97.5,126.75,156],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.4,107.36923076923077,111.33846153846154,115.3076923076923,119.27692307692308,123.24615384615385,127.21538461538462,131.1846153846154,135.15384615384616,139.12307692307692,143.09230769230768,147.06153846153848,151.03076923076924,{"y":155,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.4,105.54871794871795,107.69743589743591,109.84615384615385,111.9948717948718,114.14358974358976,116.2923076923077,118.44102564102565,120.58974358974359,122.73846153846155,124.8871794871795,127.03589743589745,129.1846153846154,{"y":131.33333333333334,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.4,104.06153846153846,104.72307692307693,105.38461538461539,106.04615384615386,106.70769230769231,107.36923076923077,108.03076923076924,108.6923076923077,109.35384615384615,110.01538461538462,110.67692307692307,111.33846153846154,{"y":112,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":42.96,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.66,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.81,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.62,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":90.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.93,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":80.71,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.47,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$155.00Average Price Target$131.33Lowest Price Target$112.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on KYMR
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$132
Buy
19.38%
Upside
Reiterated
08/13/26
Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125→$123
Buy
11.24%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Buy on Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$129
Buy
16.67%
Upside
Reiterated
08/06/26
Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Wells Fargo Analyst forecast on KYMR
Derek Archila
Wells Fargo
Wells Fargo
$116
Buy
4.91%
Upside
Reiterated
08/06/26
Kymera Therapeutics (KYMR) Receives a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on KYMR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$134
Buy
21.19%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$120→$135
Buy
22.09%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), Kymera Therapeutics (NASDAQ: KYMR) and Rigel (NASDAQ: RIGL)
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
$120→$121
Buy
9.43%
Upside
Reiterated
08/06/26
Kymera Therapeutics (KYMR) Gets a Buy from J.P. Morgan
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$119→$135
Buy
22.09%
Upside
Assigned
08/06/26
Kymera: Advancing STAT6 Pipeline, De-Risking Milestones, and Raised Price Target to $135 Support Buy Rating
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133→$139
Buy
25.71%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$115→$112
Hold
1.29%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
UBS Analyst forecast on KYMR
David Dai
UBS
UBS
$128
Buy
15.76%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Deutsche Bank Analyst forecast on KYMR
David Hoang
Deutsche Bank
Deutsche Bank
$120
Hold
8.53%
Upside
Initiated
07/29/26
Kymera Therapeutics initiated with a Hold at Deutsche BankKymera Therapeutics initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$125→$135
Buy
22.09%
Upside
Reiterated
07/28/26
KBIO’s KT-579 IRF5 Degrader Drives Buy Rating as Analyst Lifts Price Target to $135 on Lupus Upside Potential
Mizuho Securities Analyst forecast on KYMR
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$120→$140
Buy
26.62%
Upside
Reiterated
07/16/26
Kymera Therapeutics price target raised to $140 from $120 at MizuhoKymera Therapeutics price target raised to $140 from $120 at Mizuho
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
26.62%
Upside
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Stifel Nicolaus Analyst forecast on KYMR
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$132
Buy
19.38%
Upside
Reiterated
08/13/26
Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst
Bank of America Securities Analyst forecast on KYMR
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$125→$123
Buy
11.24%
Upside
Reiterated
08/07/26
Bank of America Securities Remains a Buy on Kymera Therapeutics (KYMR)
Canaccord Genuity Analyst forecast on KYMR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$129
Buy
16.67%
Upside
Reiterated
08/06/26
Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
Wells Fargo Analyst forecast on KYMR
Derek Archila
Wells Fargo
Wells Fargo
$116
Buy
4.91%
Upside
Reiterated
08/06/26
Kymera Therapeutics (KYMR) Receives a Buy from Wells Fargo
H.C. Wainwright Analyst forecast on KYMR
Andrew Fein
H.C. Wainwright
H.C. Wainwright
$134
Buy
21.19%
Upside
Reiterated
08/06/26
Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis
Citi Analyst forecast on KYMR
Geoff Meacham
Citi
Citi
$120→$135
Buy
22.09%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (NYSE: RCUS), Kymera Therapeutics (NASDAQ: KYMR) and Rigel (NASDAQ: RIGL)
J.P. Morgan Analyst forecast on KYMR
Brian Cheng
J.P. Morgan
J.P. Morgan
$120→$121
Buy
9.43%
Upside
Reiterated
08/06/26
Kymera Therapeutics (KYMR) Gets a Buy from J.P. Morgan
Morgan Stanley Analyst forecast on KYMR
Judah Frommer
Morgan Stanley
Morgan Stanley
$119→$135
Buy
22.09%
Upside
Assigned
08/06/26
Kymera: Advancing STAT6 Pipeline, De-Risking Milestones, and Raised Price Target to $135 Support Buy Rating
Barclays Analyst forecast on KYMR
Eliana Merle
Barclays
Barclays
$133→$139
Buy
25.71%
Upside
Reiterated
08/06/26
Barclays Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
RBC Capital Analyst forecast on KYMR
Brian Abrahams
RBC Capital
RBC Capital
$115→$112
Hold
1.29%
Upside
Reiterated
08/05/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Korro Bio (NASDAQ: KRRO), Ardelyx (NASDAQ: ARDX) and Kymera Therapeutics (NASDAQ: KYMR)
UBS Analyst forecast on KYMR
David Dai
UBS
UBS
$128
Buy
15.76%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Arcutis Biotherapeutics (NASDAQ: ARQT) and Agilon Health (NYSE: AGL)
Deutsche Bank Analyst forecast on KYMR
David Hoang
Deutsche Bank
Deutsche Bank
$120
Hold
8.53%
Upside
Initiated
07/29/26
Kymera Therapeutics initiated with a Hold at Deutsche BankKymera Therapeutics initiated with a Hold at Deutsche Bank
Guggenheim Analyst forecast on KYMR
Bradley Canino
Guggenheim
Guggenheim
$125→$135
Buy
22.09%
Upside
Reiterated
07/28/26
KBIO’s KT-579 IRF5 Degrader Drives Buy Rating as Analyst Lifts Price Target to $135 on Lupus Upside Potential
Mizuho Securities Analyst forecast on KYMR
Joseph Catanzaro
Mizuho Securities
Mizuho Securities
$120→$140
Buy
26.62%
Upside
Reiterated
07/16/26
Kymera Therapeutics price target raised to $140 from $120 at MizuhoKymera Therapeutics price target raised to $140 from $120 at Mizuho
Piper Sandler Analyst forecast on KYMR
Biren Amin
Piper Sandler
Piper Sandler
$140
Buy
26.62%
Upside
Reiterated
07/16/26
Analysts Conflicted on These Healthcare Names: aTyr Pharma (NASDAQ: ATYR), Kymera Therapeutics (NASDAQ: KYMR) and Cannara Biotech (Other OTC: LOVFF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
GHRSGH Research
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Kymera Therapeutics

3 Months
Judah FrommerMorgan Stanley
Success Rate
9/10 ratings generated profit
90%
Average Return
+33.30%
Copying Judah Frommer's trades and holding each position for 3 Months would result in 90.00% of your transactions generating a profit, with an average return of +33.30% per trade.
1 Year
Jeet MukherjeeBTIG
Success Rate
12/12 ratings generated profit
100%
Average Return
+97.01%
Copying Jeet Mukherjee's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +97.01% per trade.
2 Years
Faisal KhurshidJefferies
Success Rate
12/12 ratings generated profit
100%
Average Return
+193.45%
Copying Faisal Khurshid's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +193.45% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KYMR Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
3
4
5
3
1
Buy
18
16
22
22
28
Hold
0
0
0
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
21
20
27
27
32
In the current month, KYMR has received 29 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. KYMR average Analyst price target in the past 3 months is 131.33.
Each month's total comprises the sum of three months' worth of ratings.

KYMR Financial Forecast

KYMR Earnings Forecast

Next quarter’s earnings estimate for KYMR is -$1.24 with a range of -$1.44 to -$0.93. The previous quarter’s EPS was -$0.62. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s earnings estimate for KYMR is -$1.24 with a range of -$1.44 to -$0.93. The previous quarter’s EPS was -$0.62. KYMR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Sales Forecast

Next quarter’s sales forecast for KYMR is $3.82M with a range of -$1.00M to $20.00M. The previous quarter’s sales results were $65.00M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.
Next quarter’s sales forecast for KYMR is $3.82M with a range of -$1.00M to $20.00M. The previous quarter’s sales results were $65.00M. KYMR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year KYMR has Performed in-line its overall industry.

KYMR Stock Forecast FAQ

What is KYMR’s average 12-month price target, according to analysts?
Based on analyst ratings, Kymera Therapeutics, Inc.’s 12-month average price target is 131.33.
    What is KYMR’s upside potential, based on the analysts’ average price target?
    Kymera Therapeutics, Inc. has 18.78% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is KYMR a Buy, Sell or Hold?
          Kymera Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 16 buy ratings, 2 hold ratings and 0 sell ratings.
            What is Kymera Therapeutics, Inc.’s price target?
            The average price target for Kymera Therapeutics, Inc. is 131.33. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $155.00 ,the lowest forecast is $112.00. The average price target represents 18.78% Increase from the current price of $110.57.
              What do analysts say about Kymera Therapeutics, Inc.?
              Kymera Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of KYMR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.